ARTICLE | Clinical News
Gleevec imatinib regulatory update
October 1, 2001 7:00 AM UTC
NVS received Canadian marketing approval for Gleevec to treat chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase after failure of interferon alpha therapy. Gleevec is approve...